An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
Phase of Trial: Phase IV
Latest Information Update: 11 Jan 2019
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms TOURMALINE MM-6
- Sponsors Takeda Oncology
- 26 Feb 2018 Planned End Date changed from 31 Aug 2023 to 30 Nov 2023.
- 26 Feb 2018 Planned primary completion date changed from 31 Aug 2023 to 30 Nov 2023.
- 17 Oct 2017 Status changed from not yet recruiting to recruiting.